The Income Tax Appellate Tribunal (ITAT) has ruled that the net profit during the demonetization period from medicine business should be estimated at 4% of gross sales, allowing the appeal from the assessee. The tribunal directed the Assessing Officer (AO) to charge tax at normal rates and entitled the assessee to consequential relief.
Net Profit in Demonetization Period from Medicine Business Estimated at 4%
The Income Tax Appellate Tribunal (ITAT) has ruled in favor of an assessee, stating that the net profit during the demonetization period from the medicine business should be estimated at 4% of gross sales. This decision allows the appeal from the taxpayer and leads to the direction for the Assessing Officer (AO) to charge tax at normal rates.
The tribunal’s ruling emphasizes the importance of considering a fair estimation method for profits during challenging periods such as demonetization. The ITAT recognized the unique circumstances surrounding the medicine business during the demonetization drive, which resulted in varying sales patterns.
In its directive, the ITAT acknowledged the necessity of consequential relief for the assessee after ruling against a higher tax rate. This move aligns with the principles of fair taxation during extraordinary financial conditions.
The implications for tax practitioners are significant, as this ruling provides a clear benchmark for estimating income from sales in the healthcare sector during periods of significant economic change. Assessors should be prepared to justify their calculation methods meaningfully in light of this precedent.
Citations
- ITAT Order (2026) Volume Reporter Page
